Details for New Drug Application (NDA): 207228
✉ Email this page to a colleague
NDA 207228 describes DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), which is a drug marketed by Ayana Pharma Ltd, Baxter Hlthcare Corp, Dr Reddys, Lupin, Sun Pharm, and Zydus Lifesciences, and is included in six NDAs. It is available from seven suppliers. Additional details are available on the DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) profile page.
The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
Summary for 207228
| Tradename: | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) |
| Applicant: | Ayana Pharma Ltd |
| Ingredient: | doxorubicin hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 207228
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE, LIPOSOMAL;INJECTION | Strength | 20MG/10ML (2MG/ML) | ||||
| Approval Date: | Oct 12, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE, LIPOSOMAL;INJECTION | Strength | 50MG/25ML (2MG/ML) | ||||
| Approval Date: | Oct 12, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
